RxDoctor Payments Data

Marloe Prince, MD

Interventional Cardiology · Kingwood, TXNPI 1740696343

Payments from drug & device makers

$97,211in general payments, 2019–2025

Across 555 payments — averaging $175.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Recor Medical Inc$41K
  • Abiomed$24K
  • Medtronic$7K
  • Angiodynamics, Inc.$6K
  • Siemens Medical Solutions USA, Inc.$4K
  • Boston Scientific$3K
  • plus $12K from 35 others
$2,000in research payments, 2019–2025

Across 1 payment — averaging $2000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$2K

What the payments were for

  • Consulting fees$9,96016%
  • Speaking & faculty fees$12,68021%
  • Travel & lodging$14,56824%
  • Food & beverage$23,49038%
  • Education$6581%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$97,211 in reported general payments places this provider in the 85th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$519,222
Medicare patients
934
Services billed
3,947

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban42$49,579
XareltoRivaroxaban49$39,069
EntrestoSacubitril/Valsartan39$32,995
OzempicSemaglutide21$19,820
Repatha SureclickEvolocumab35$19,582
FarxigaDapagliflozin Propanediol12$10,999
Prasugrel Hcl40$4,826
Metoprolol Succinate87$1,145
ClopidogrelClopidogrel Bisulfate76$704
Nifedipine ErNifedipine21$673
Losartan Potassium57$639
Atorvastatin Calcium77$585
Metolazone28$559
Bumetanide11$442
Chlorthalidone26$432

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$466$49,57942 claims
Johnson & JohnsonXarelto$689$39,06949 claims
NovartisEntresto$156$32,99539 claims
Novo NordiskOzempic$390$19,82021 claims
AstraZenecaFarxiga$417$10,99912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Kingwood

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →